Related Experiment Video

Updated: Oct 23, 2025

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

52

Management and Outcome of Coronavirus Disease 2019 (COVID-19) in Pediatric Cancer Patients: A Single Centre

Mahmoud Hammad1, Lobna Shalaby1, Iman Sidhom1

  • 1Pediatric Oncology Department National Cancer Institute, Cairo University and Children's Cancer Hospital Egypt (CCHE-57357). Cairo, Egypt.

Clinical Lymphoma, Myeloma & Leukemia
|August 23, 2021
PubMed

Insights

Most pediatric cancer patients recover well from Coronavirus disease 2019 (COVID-19). Critical infections pose the highest risk, but chemotherapy can often continue during COVID-19 treatment.

Area of Science:

  • Pediatric Oncology
  • Infectious Diseases
  • Hematology-Oncology

Background:

  • Limited data exists on Coronavirus disease 2019 (COVID-19) impact in pediatric cancer patients.
  • Understanding clinical management and outcomes is crucial for this vulnerable population.

Purpose of the Study:

  • To prospectively describe the clinical management and outcomes of pediatric oncology patients diagnosed with COVID-19.

Main Methods:

  • Prospective study of 76 pediatric oncology patients with confirmed COVID-19 between May and November 2020.
  • Data collection on clinical presentation, management (including Remdesivir use), and outcomes.

Main Results:

  • Fever was the most common symptom (93.4%); 35.4% had severe to critical infections.
  • Chemotherapy was delayed in 59.2% and modified in 30.2%.
  • Overall survival at 60 days was 86.8%, with mortality only in critical cases. Remdesivir showed comparable survival despite higher severe infection rates.

Conclusions:

  • Pediatric cancer patients generally have good outcomes with COVID-19, barring critical illness.
  • Chemotherapy, including induction, is often tolerable during COVID-19 treatment.
  • Remdesivir may offer benefits in severe to critical COVID-19 cases.
Abstract

Keywords:
COVID-19SARS-CoV-2immunocompromised patientspediatric cancerremdesivir

More Related Videos

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System10:24

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

Published on: October 5, 2015

12.6K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.6K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
56
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
46
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
39
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
44
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
481